Navigation Links
Aeterna Zentaris: Perifosine Data Selected for Oral Presentation at Upcoming 12th World Congress on Gastrointestinal Cancer
Date:6/29/2010

itor, is currently in Phase 3 trials for advanced colorectal cancer and multiple myeloma, under SPA and Fast Track designation granted by the FDA for both indications. Perifosine has also been granted orphan-drug status by the FDA for multiple myeloma and has received a positive opinion for Orphan Medicinal Product designation from the European Medicines Agency (EMA) in this same indication. In addition, perifosine has received positive Scientific Advice from the EMA for both multiple myeloma and colorectal cancer programs.

Perifosine is also in a Phase 1 trial in pediatric patients, as well as in other Phase 1 and Phase 2 trials for several other tumor types.

Perifosine is licensed to Keryx, in the United States, Canada and Mexico. Aeterna Zentaris has also out-licensed perifosine to Handok in South Korea, while retaining rights for the rest of the world.

About Colorectal Cancer

According to the American Cancer Society, colorectal cancer is the third most common form of cancer diagnosed in the United States. It is estimated that in the U.S., over 146,000 people were diagnosed with some form of colorectal cancer with over 49,000 patients dying from colorectal cancer in 2009. Surgery is often the main treatment for early stage colorectal cancer. When colorectal cancer metastasizes (spreads to other parts of the body such as the liver) chemotherapy is commonly used. Treatment of patients with recurrent or advanced colorectal cancer depends on the location of the disease. Chemotherapy regimens (i.e. FOLFOX or FOLFIRI either with or without bevacizumab) have been shown to increase survival rates in patients with metastatic/advanced colorectal cancer. Currently, there are seven app
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Aeterna Zentaris Announces Collaboration with Almac to Develop Therapy and Companion Diagnostic in Cancer
2. Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering
3. Aeterna Zentaris to Raise US$12 Million in Registered Direct Offering
4. Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency
5. Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
6. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
7. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
8. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
9. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
10. AEterna Zentaris Announces Appointment of New Board Member
11. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... 2014 Research and Markets has ... Photoresist Industry Report 2014" report to their offering. ... Report 2014 is a professional and in-depth study on ... industry . The report provides a basic ... industry chain structure. The dry film photoresist market analysis ...
(Date:9/12/2014)... NM (PRWEB) September 12, 2014 Sandia ... an exclusive option agreement with STC.UNM (STC) for a ... Mexico (UNM) in Albuquerque, New Mexico, and Queen Mary ... of technologies, called the Recombinant Fluorescent Antibody Technology Platform ... Department of Internal Medicine and Dr. Angray Kang from ...
(Date:9/11/2014)... it has uncovered the secret behind the unusual ... metal dichalcogenide (TMDC) materials, the two-dimensional semiconductors that ... , Using two-photon excitation spectroscopy, the researchers ... most promising of 2D materials, and found evidence ... energy states in which single photons can be ...
(Date:9/11/2014)... a research paper published this week in Science ... Levitov and Manchester,s Nobel laureate Sir Andre Geim report ... angle to applied fields, similar to sailboats driven diagonally ... one atom-thick chicken wire made from carbon but ... so-called superlattice state by placing it on top of ...
Breaking Biology Technology:Global Dry Film Photoresist Industry Report 2014 2Sandia Biotech and STC.UNM Announce Option Agreement to License Novel Recombinant Antibody Technology 2Sandia Biotech and STC.UNM Announce Option Agreement to License Novel Recombinant Antibody Technology 3Sandia Biotech and STC.UNM Announce Option Agreement to License Novel Recombinant Antibody Technology 4Excitonic dark states shed light on TMDC atomic layers 2Excitonic dark states shed light on TMDC atomic layers 3New species of electrons can lead to better computing 2
... privately held,medical device firm, announced that it has successfully ... Crux IVC Filter. The filter, used to,prevent an often ... Center by David Rosenthal, Chief of Vascular Surgery. Every,year ... PE and,between 120,000 - 150,000 die as a result. ...
... Influenza ... Testing, ... company developing rapid molecular diagnostics and detection,systems, announces a EUR3 million ... The award will fund the,development and validation of a fully automated, ...
... More Than Doubles Assets Under Management, UTRECHT, The ... European venture capital firm, today announced,the closing of its ... II (GHC II). The new fund, which is Gilde,s ... raised to invest in European,healthcare opportunities. GHC II was ...
Cached Biology Technology:Crux Biomedical Announces First Successful U.S. Implant of Its New Retrievable Inferior Vena Cava (IVC) Filter 2Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections 2Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund 2
(Date:9/15/2014)... are produced naturally across all kingdoms of life and ... broad range of biological activities. The presence of halogen ... on their molecular properties. , One of ... find the late-stage, site-specific incorporation of a halogen atom ... C-H bond (one of the most inert chemical bonds ...
(Date:9/15/2014)... A new strategic vision document, released today ... Program, describes the long-term goals, objectives, and strategies ... of work over the next five years (2015-2020). ... initial, short-term activities, to be funded in 2015, ... science policy fellowships. , The $500 million, ...
(Date:9/15/2014)... cognitive function may play roles in one,s musical aptitude, ... timbre, tone durations, and formal structure in music. , ... that extremes in musical aptitude (extreme capacity/no capacity) are ... having moderate aptitude. , "This is a typical feature ... and it is influenced to varying degrees by environmental ...
Breaking Biology News(10 mins):Pitt chemical biologist finds new halogenation enzyme 2NAS Gulf Research Program announces strategic vision, initial opportunities 2NAS Gulf Research Program announces strategic vision, initial opportunities 3NAS Gulf Research Program announces strategic vision, initial opportunities 4
... growing asthma rates among children with exposure to ... study in the May issue of Journal ... Levels in North Carolina Schools: Comparison of Integrated ... using integrated pest management (IPM) to control cockroaches ...
... has implicated machinery that maintains the flow of potassium in ... Expression of a previously unknown form of a key such ... normal in the brain memory hub of people with the ... variation. An extensive series of experiments suggest that ...
... May 5, 2009 Researchers at the Hebrew University ... the tumor-risk factor in utilizing human embryonic stem cells. ... the promising field of stem cell therapy. ... to all cells of the mature human body (and ...
Cached Biology News:Flow of potassium into cells implicated in schizophrenia 2Flow of potassium into cells implicated in schizophrenia 3Hebrew University researchers neutralize tumor growth in embryonic stem cell therapy 2
... benchtop fume hood ventilates and ... indoor release of exhaust. Bonded ... contaminants. Configurations are available with ... include final HEPA filter, work ...
... modular cleanroom for biological safety labs ... cleanliness (to Class 10/ISO 3) and ... create ultra-smooth surfaces that are easy ... radius corners simplify cleaning. Unique double-wall ...
... new Hummingbird has the ability to quickly and ... makes it a perfect candidate for inclusion in ... OCX interface supplied with all the Cartesian products ... Hummingbirds ability to copy plates in seconds ...
This modular benchtop fume hood ventilates and purifies chemical fumes, allowing safe indoor release of exhaust. Bonded charcoal filters remove most organic contaminants. Options include final HEPA f...
Biology Products: